Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation

Background: Glioblastoma (GBM) is the most common brain tumor with an overall survival (OS) of less than 30% at two years. Valproic acid (VPA) demonstrated survival benefits documented in retrospective and prospective trials, when used in combination with chemo-radiotherapy (CRT). Purpose: The prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Krauze, Andra V., Zhao, Yingdong, Li, Ming-Chung, Shih, Joanna, Jiang, Will, Tasci, Erdal, Cooley Zgela, Theresa, Sproull, Mary, Mackey, Megan, Shankavaram, Uma, Tofilon, Philip, Camphausen, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604983/
https://www.ncbi.nlm.nih.gov/pubmed/37892181
http://dx.doi.org/10.3390/biom13101499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604983/
https://www.ncbi.nlm.nih.gov/pubmed/37892181
http://dx.doi.org/10.3390/biom13101499

Ejemplares similares